These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21926631)

  • 1. Incorporation of the HIV-1 microbicide cyanovirin-N in a food product.
    Li M; Patton DL; Cosgrove-Sweeney Y; Ratner D; Rohan LC; Cole AM; Tarwater PM; Gupta P; Ramratnam B
    J Acquir Immune Defic Syndr; 2011 Dec; 58(4):379-84. PubMed ID: 21926631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
    Cranage M; Sharpe S; Herrera C; Cope A; Dennis M; Berry N; Ham C; Heeney J; Rezk N; Kashuba A; Anton P; McGowan I; Shattock R
    PLoS Med; 2008 Aug; 5(8):e157; discussion e157. PubMed ID: 18684007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques.
    Tsai CC; Emau P; Jiang Y; Tian B; Morton WR; Gustafson KR; Boyd MR
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):535-41. PubMed ID: 12921090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models.
    Tsai CC; Emau P; Jiang Y; Agy MB; Shattock RJ; Schmidt A; Morton WR; Gustafson KR; Boyd MR
    AIDS Res Hum Retroviruses; 2004 Jan; 20(1):11-8. PubMed ID: 15000694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N.
    Liu X; Lagenaur LA; Simpson DA; Essenmacher KP; Frazier-Parker CL; Liu Y; Tsai D; Rao SS; Hamer DH; Parks TP; Lee PP; Xu Q
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3250-9. PubMed ID: 17005802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioengineering lactic acid bacteria to secrete the HIV-1 virucide cyanovirin.
    Pusch O; Boden D; Hannify S; Lee F; Tucker LD; Boyd MR; Wells JM; Ramratnam B
    J Acquir Immune Defic Syndr; 2005 Dec; 40(5):512-20. PubMed ID: 16284525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models.
    Buffa V; Stieh D; Mamhood N; Hu Q; Fletcher P; Shattock RJ
    J Gen Virol; 2009 Jan; 90(Pt 1):234-43. PubMed ID: 19088294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation and delivery of anti-HIV rectal microbicides: advances and challenges.
    Nunes R; Sarmento B; das Neves J
    J Control Release; 2014 Nov; 194():278-94. PubMed ID: 25229988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyanovirin-N produced in rice endosperm offers effective pre-exposure prophylaxis against HIV-1BaL infection in vitro.
    Vamvaka E; Evans A; Ramessar K; Krumpe LR; Shattock RJ; O'Keefe BR; Christou P; Capell T
    Plant Cell Rep; 2016 Jun; 35(6):1309-19. PubMed ID: 27007716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Concepts for the IND-Directed Development of Microbicide Products to Prevent the Sexual Transmission of HIV.
    Buckheit KW; Furlan-Freguia C; Ham AS; Buckheit RW
    Curr Top Med Chem; 2016; 16(10):1118-34. PubMed ID: 26324047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rectal microbicide development.
    McGowan I; Dezzutti C
    Curr Top Microbiol Immunol; 2014; 383():117-36. PubMed ID: 23612991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides.
    Fletcher PS; Elliott J; Grivel JC; Margolis L; Anton P; McGowan I; Shattock RJ
    AIDS; 2006 Jun; 20(9):1237-45. PubMed ID: 16816551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Properties of cyanovirin-N (CV-N): inactivation of HIV-1 by sessile cyanovirin-N (sCV-N).
    Gandhi MJ; Boyd MR; Yi L; Yang GG; Vyas GN
    Dev Biol (Basel); 2000; 102():141-8. PubMed ID: 10794101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical development of microbicides for the prevention of HIV infection.
    D'Cruz OJ; Uckun FM
    Curr Pharm Des; 2004; 10(3):315-36. PubMed ID: 14754390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colorectal microbicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants.
    Herrera C; Cranage M; McGowan I; Anton P; Shattock RJ
    AIDS; 2011 Oct; 25(16):1971-9. PubMed ID: 21811139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential use of protease inhibitors as vaginal and colorectal microbicides.
    Herrera C; Shattock RJ
    Curr HIV Res; 2012 Jan; 10(1):42-52. PubMed ID: 22264045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model.
    Patton DL; Sweeney YT; Paul KJ
    Sex Transm Dis; 2009 Jun; 36(6):350-6. PubMed ID: 19556929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rectal microbicides in development.
    Willyard C
    Nat Med; 2009 Aug; 15(8):829. PubMed ID: 19661974
    [No Abstract]   [Full Text] [Related]  

  • 19. Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis.
    Richardson-Harman N; Lackman-Smith C; Fletcher PS; Anton PA; Bremer JW; Dezzutti CS; Elliott J; Grivel JC; Guenthner P; Gupta P; Jones M; Lurain NS; Margolis LB; Mohan S; Ratner D; Reichelderfer P; Roberts P; Shattock RJ; Cummins JE
    J Clin Microbiol; 2009 Nov; 47(11):3530-9. PubMed ID: 19726602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study.
    Richardson-Harman N; Mauck C; McGowan I; Anton P
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1422-33. PubMed ID: 22900504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.